Balaji Amines
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Balaji Amines is strategically transitioning towards high-value specialty chemicals, supported by a significant ₹1000 Cr capex cycle nearing completion. Management's confidence stems from the successful launch of India's first commercial-scale DME plant and expansions in NMM and ACN, which are expected to enhance production capacity and revenue. This pivot aligns with Vista's forecast of accelerating revenue growth and improving margins, as the company capitalizes on strong domestic demand and favorable trade agreements. However, execution risks related to the simultaneous ramp-up of multiple facilities and volatility in raw material prices pose challenges. The specialty chemicals sector's resilience amid competitive pressures and the anticipated recovery in demand further bolster the outlook. Over the next 12-24 months, key opportunities include scaling high-value derivatives for pharmaceuticals and EV batteries, while watchpoints include geopolitical tensions and the stabilization of new capacities. Overall, Vista's expected upside of 12.1% reflects confidence in Balaji Amines' growth trajectory, with a target price of ₹2831
Why We Like This Stock
- Successful launch of India's first commercial-scale DME plant enhances revenue potential
- Significant capex investments are expected to drive margin expansion and production capacity
- Strong domestic demand and favorable trade agreements support long-term growth prospects
Things To Watch Out For
- Execution risks from ramping up multiple new facilities could hinder growth
- Volatility in raw material prices may impact margins and profitability
- Geopolitical tensions could affect demand and operational stability
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,631 | 1,389 | 1,425 | 1,667 | 1,841 |
| Profit Before Tax (Cr.) | 302 | 213 | 232 | 309 | 332 |
| PBT Margin | 18.5% | 15.3% | 16.3% | 18.5% | 18.1% |
| Net Profit (Cr.) | 232 | 169 | 184 | 246 | 262 |
| Earnings Per Share | 63.0 | 51.7 | 56.1 | 74.9 | 80.5 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| CD Equisearch | ▲ Buy | 3,327 | 10-Jul-2026 |
| BOB Capital Markets | ► Hold | 1,981 | 20-May-2026 |
| Moneycontrol | ▲ Overweight | nan | 20-May-2026 |
Company Overview
Show Company Profile
Balaji Amines Limited engages in the manufacture and sale of methylamines, ethylamines, and derivatives of specialty chemicals and pharma excipients in India and internationally. The company operates in two segments, Chemicals and Hotel. It offers monomethylamine, dimethylamine, trimethylamine, monoethylamine, diethylamine, triethylamine, and dimethyl and diethyl amino ethanol; and specialty chemicals, including N-methyl pyrrolidone, morpholine, 2-pyrrolidone, N-ethyl-2-pyrrolidone, gamma-butyrolactone, dimethylformamide, acetonitrile, dimethylcarbonate, propylene glycol, and propylene carbonate. The company also provides derivatives comprising di-methyl acetamide, di-methyl amine hydrochloride, tri-methyl amine hydrochloride, di-ethyl amine hydrochloride, tri-ethyl amine hydrochloride, di-methyl urea, choline chloride, mono-ethyl amine hydrochloride, and benzyl tri ethyl ammonium chloride; and pharma excipients, such as poly vinyl pyrrolidone. It also provides hotels, restaurants, and hospitality services. The company also exports its products to Europe, the United States, and Japan. Balaji Amines Limited was incorporated in 1988 and is headquartered in Hyderabad, India.